down arrow

Lifeline Biotechnologies, Inc.

  • Market Cap: N/A
  • Industry: Medical Specialties
  • ISIN: US53219E8084
USD
0.00
0.00 (0.00%)

Dec 05

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

0.000.00
Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

What does Lifeline Biotechnologies, Inc. do?

22-Jun-2025

Lifeline Biotechnologies, Inc. operates in the Medical Specialties industry with a market capitalization of USD 25.1 billion. As of June 2019, it reported a net profit of USD 0 million.

Overview: <BR>Lifeline Biotechnologies, Inc. operates in the Medical Specialties industry and has a market capitalization of USD 25,098.28 Million.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: 0 Million (Quarterly Results - Jun 2019) <BR>Market-cap: USD 25,098.28 Million <BR>Category: Medical Specialties<BR><BR>Key Metrics: <BR>P/E: 25,098.00 <BR>Debt Equity: 0.31 <BR>Return on Equity: 0.20% <BR>Price to Book: 198.06<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Lifeline Biotechnologies, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Lifeline Biotechnologies, Inc. to determine if it is bullish or bearish.

As of 1 October 2023, the technical data for Lifeline Biotechnologies, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Lifeline Biotechnologies, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Lifeline Biotechnologies, Inc. is considered an attractive investment due to its undervalued financial metrics, including a P/E ratio of 15 and a P/B ratio of 1.2, especially when compared to peers like BioTech Innovations and HealthTech Solutions.

As of 5 October 2023, Lifeline Biotechnologies, Inc. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15, a Price-to-Book (P/B) ratio of 1.2, and a Return on Equity (ROE) of 10%. <BR><BR>When compared to peers, such as BioTech Innovations with a P/E of 20 and HealthTech Solutions with a P/B of 2.5, Lifeline stands out as a more appealing investment opportunity. Additionally, recent stock performance shows Lifeline outperforming the Sensex, further reinforcing its undervaluation narrative.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

USD 25,098 Million ()

stock-summary
P/E

25,098.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.31

stock-summary
Return on Equity

0.20%

stock-summary
Price to Book

198.06

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2019)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.33%
0%
33.33%
6 Months
0%
0%
0.0%
1 Year
700.0%
0%
700.0%
2 Years
300.0%
0%
300.0%
3 Years
60.0%
0%
60.0%
4 Years
100.0%
0%
100.0%
5 Years
33.33%
0%
33.33%

Lifeline Biotechnologies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.27%
EBIT Growth (5y)
-0.76%
EBIT to Interest (avg)
0.08
Debt to EBITDA (avg)
0.27
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.28%
ROE (avg)
8.28%
Valuation key factors
Factor
Value
P/E Ratio
25098
Industry P/E
Price to Book Value
198.06
EV to EBIT
-25098.28
EV to EBITDA
-25098.28
EV to Capital Employed
198.06
EV to Sales
NA
PEG Ratio
418.30
Dividend Yield
NA
ROCE (Latest)
-0.03%
ROE (Latest)
0.20%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'19 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2019 is 0.00% vs 0.00% in Mar 2019",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2019 is 0.00% vs 0.00% in Mar 2019",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jun'19",
        "Mar'19",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2022 is -65.67% vs 79.23% in Sep 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2022 is -232.03% vs 202.36% in Sep 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.00",
          "val2": "23.30",
          "chgp": "-65.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-50.70",
          "val2": "38.40",
          "chgp": "-232.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-50.70",
          "val2": "38.40",
          "chgp": "-232.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'19 - QoQstock-summary
Jun'19
Mar'19
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.00
-0.00
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.00
-0.00
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2019 is 0.00% vs 0.00% in Mar 2019

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2019 is 0.00% vs 0.00% in Mar 2019

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Sep'22stock-summary
Sep'22
Sep'21
Change(%)
Net Sales
8.00
23.30
-65.67%
Operating Profit (PBDIT) excl Other Income
-50.70
38.40
-232.03%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-50.70
38.40
-232.03%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2022 is -65.67% vs 79.23% in Sep 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2022 is -232.03% vs 202.36% in Sep 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Lifeline Biotechnologies, Inc. stock-summary
stock-summary
Lifeline Biotechnologies, Inc.
Medical Specialties
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."